Journal of Hematology & Oncology

Article	Citations
Targeting the Wnt/β-catenin signaling pathway in cancer	823
Nanomaterials for cancer therapy: current progress and perspectives	671
Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer	463
NK cell-based cancer immunotherapy: from basic biology to clinical development	397
Regulation of PD-L1 expression in the tumor microenvironment	365
Challenges and advances in clinical applications of mesenchymal stromal cells	348
Next generation of immune checkpoint inhibitors and beyond	347
Cancer vaccines as promising immuno-therapeutics: platforms and current progress	336
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis	323
RNA sequencing: new technologies and applications in cancer research	316
Liquid biopsy: current technology and clinical applications	315
Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research	308
Combination strategies to maximize the benefits of cancer immunotherapy	307
Recent advances in therapeutic strategies for triple-negative breast cancer	283
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling	277
Isolation and characterization of exosomes for cancer research	274
Applications of single-cell sequencing in cancer research: progress and perspectives	274
Neutrophils in cancer carcinogenesis and metastasis	268
Targeting mutant p53 for cancer therapy: direct and indirect strategies	266
Novel therapies emerging in oncology to target the TGF-β pathway	255
Immunosenescence: a key player in cancer development	252
Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response	250
Targeting hypoxic tumor microenvironment in pancreatic cancer	238
Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions	235
Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells	235

Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets	219
Burden of anemia and its underlying causes in 204 countries and territories, 1990–2019: results from the Global Burden of Disease Study 2019	217
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy	215
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation	207
Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer	200
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)	198
Gastric cancer treatment: recent progress and future perspectives	196
Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy	196
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies	195
Targeting CD47 for cancer immunotherapy	190
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape	189
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy	180
Targeting MCL-1 in cancer: current status and perspectives	177
MEK inhibitors for the treatment of non-small cell lung cancer	173
HMGB1 released from GSDME-mediated pyroptotic epithelial cells participates in the tumorigenesis of colitis-associated colorectal cancer through the ERK1/2 pathway	169
Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies	167
Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990–2019	167
Role of lysosomes in physiological activities, diseases, and therapy	164
The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update	159
Mesenchymal stem/stromal cells in cancer therapy	158
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends	156
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin	154
Exploring immunotherapy in colorectal cancer	151
Antibody–drug conjugates in solid tumors: a look into novel targets	146
The management of metastatic GIST: current standard and investigational therapeutics	144
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single insti	144
N6-methyladenosine methyltransferases: functions, regulation, and clinical potential	143
Targeting autophagy to overcome drug resistance: further developments	142
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies	139
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1	139
Emerging agents and regimens for AML	138
Targeting Akt in cancer for precision therapy	132
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts	129
The potential role of N7-methylguanosine (m7G) in cancer	126
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy	125
Emerging strategies to target RAS signaling in human cancer therapy	121
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma	118
The long and short non-coding RNAs modulating EZH2 signaling in cancer	116
HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk	116
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma	112
Development of a novel combined nomogram model integrating deep learning-pathomics, radiomics and immunoscore to predict postoperative outcome of colorectal cancer lung metastasis patients	112
The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia	112
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance	111
The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands	110
Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications	109
Contradictory roles of lipid metabolism in immune response within the tumor microenvironment	106
MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents	103
A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties	102
YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of glioma	101
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021	100

Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer	99
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials	98
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies	97
RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential	96
New agents and regimens for diffuse large B cell lymphoma	95
Advances in the diagnosis and treatment of sickle cell disease	93
Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma	92
Tumor organoids: applications in cancer modeling and potentials in precision medicine	91
LCAT3, a novel m6A-regulated long non-coding RNA, plays an oncogenic role in lung cancer via binding with FUBP1 to activate c-MYC	91
Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors	89
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks	88
FGFR-TKI resistance in cancer: current status and perspectives	88
HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA	88
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management	87
Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer	87
Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers	86
Reactive oxygen species (ROS) scavenging biomaterials for anti-inflammatory diseases: from mechanism to therapy	85
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors	85
STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib	84
Prostate cancer and PARP inhibitors: progress and challenges	82
CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR	81
T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors	81
CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation	81
Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity	81
LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma	81
Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses	79
Targeting macrophages in hematological malignancies: recent advances and future directions	78
Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy	78
Payload diversification: a key step in the development of antibody–drug conjugates	78
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)	77
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma	76
Born to survive: how cancer cells resist CAR T cell therapy	75
Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy	74
Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma	72
Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies	72
Recent advances in targeted therapies in acute myeloid leukemia	71
Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy	71
Emerging strategies to overcome resistance to third-generation EGFR inhibitors	71
Metabolism, metabolites, and macrophages in cancer	71
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies	71
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy	71
TGF-β signaling in the tumor metabolic microenvironment and targeted therapies	70
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia	69
Natural killer cell-based immunotherapy for acute myeloid leukemia	69
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy	69
STAT proteins: a kaleidoscope of canonical and non-canonical functions in immunity and cancer	69
Cancer cachexia: molecular mechanisms and treatment strategies	69
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy	68
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1	67
N6-methyladenosine reader IMP2 stabilizes the ZFAS1/OLA1 axis and activates the Warburg effect: implication in colorectal cancer	67
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies	67
SARS-CoV-2 interacts with platelets and megakaryocytes via ACE2-independent mechanism	66
Third-line therapy for chronic myeloid leukemia: current status and future directions	66
Circadian rhythms and cancers: the intrinsic links and therapeutic potentials	66
Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study	64
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies	63
Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics	63
The emerging role of KDM5A in human cancer	63
Prognostic and predictive biomarker developments in multiple myeloma	62
Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer	62
Thrombocytopenia and thrombosis in hospitalized patients with COVID-19	62
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target	62
Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities	62
Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors	62
Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies	62
Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party o	61
Designing strategies of small-molecule compounds for modulating non-coding RNAs in cancer therapy	61
Deep learning for differential diagnosis of malignant hepatic tumors based on multi-phase contrast-enhanced CT and clinical data	60
Burden, trends, and risk factors of esophageal cancer in China from 1990 to 2017: an up-to-date overview and comparison with those in Japan and South Korea	60
Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes	60
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy	60
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma	60
CAR-T cells and BiTEs in solid tumors: challenges and perspectives	60
Emerging agents and regimens for multiple myeloma	58
Molecular pathogenesis of the myeloproliferative neoplasms	58
Functions, mechanisms, and therapeutic implications of METTL14 in human cancer	57
Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation	56
Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism	55
CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer	54
Exosomal circRNA: emerging insights into cancer progression and clinical application potential	53

How we treat NK/T-cell lymphomas	53
Advances of medical nanorobots for future cancer treatments	53
Therapeutic strategies in RET gene rearranged non-small cell lung cancer	53
The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials	52
Recent advances in targeted strategies for triple-negative breast cancer	52
Protein degradation technology: a strategic paradigm shift in drug discovery	52